Recent studies have highlighted the role of kidney-acting drugs, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists, in the management of AF and heart failure. The gene discussed is SLC5A2; the disease is heart failure.